Capricor因主要药物修订计划而飙升 (CAPR:NASDAQ)
· seekingalpha.com
Capricor Therapeutics (CAPR)股价飙升，因公司计划为其主要药物Deramiocel针对杜氏肌营养不良症提交修订后的上市申请。更多详情请阅读此处。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...